Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhone-Poulenc Taxotere, Campto Propel Oncology Sales To 39% Growth

Executive Summary

Sales of Rhone-Poulenc's Taxotere (docetaxel) jumped 40.9% (excluding the impact of exchange rates) to $116 mil. in the second quarter, leading the firm's oncology revenues.

You may also be interested in...



Lovenox Cost-Effectiveness Over Heparin Highlighted In ACC/AHA Guidelines

The cost-effectiveness of Rhone-Poulenc Rorer's Lovenox relative to unfractionated heparin in the treatment of unstable angina/non-Q-wave myocardial infarction is discussed in the 1999 American College of Cardiology/ American Heart Association practice guidelines.

Lovenox Cost-Effectiveness Over Heparin Highlighted In ACC/AHA Guidelines

The cost-effectiveness of Rhone-Poulenc Rorer's Lovenox relative to unfractionated heparin in the treatment of unstable angina/non-Q-wave myocardial infarction is discussed in the 1999 American College of Cardiology/ American Heart Association practice guidelines.

P&U Predicts Fourth Quarter Launch For "Approvable" Antidepressant Vestra

Pharmacia & Upjohn and co-promotion partner Janssen expect a fourth quarter launch for the antidepressant Vestra (reboxetine), following FDA "approvable" designation July 29.

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel